SOPHiA GENETICS (NASDAQ:SOPH) Insider Zhenyu Xu Sells 4,000 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 4,000 shares of the stock in a transaction on Tuesday, October 13th. The shares were sold at an average price of $7.18, for a total value of $28,720.00. Following the completion of the transaction, the insider directly owned 541,493 shares in the company, valued at approximately $3,887,919.74. This represents a 0.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Monday, October 5th, Zhenyu Xu sold 7,394 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.12, for a total value of $60,039.28.
• On Thursday, August 27th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.91, for a total value of $89,100.00.
• On Thursday, August 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.52, for a total value of $30,080.00.
• On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total value of $123,930.00.
• On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.00, for a total value of $21,000.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total value of $69,200.00.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ SOPH opened at $7.06 on Thursday. The stock has a market cap of $592.26 million, a price-to-earnings ratio of -6.14 and a beta of 0.95. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. SOPHiA GENETICS SA has a 1-year low of $3.75 and a 1-year high of $8.98. The stock’s 50-day moving average is $7.97 and its 200 day moving average is $6.22.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. On average, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on SOPH. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. BTIG Research boosted their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of SOPHiA GENETICS in a research note on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, SOPHiA GENETICS has a consensus rating of “Hold” and an average price target of $10.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Large investors have recently made changes to their positions in the business. Silverberg Bernstein Capital Management LLC increased its stake in shares of SOPHiA GENETICS by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after buying an additional 4,155 shares during the period. Principal Financial Group Inc. lifted its stake in SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after acquiring an additional 9,800 shares during the period. First Dallas Securities Inc. purchased a new stake in SOPHiA GENETICS in the first quarter worth $50,000. 1492 Capital Management LLC lifted its stake in SOPHiA GENETICS by 8.4% in the first quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock worth $1,117,000 after acquiring an additional 17,406 shares during the period. Finally, Royal Bank of Canada boosted its holdings in SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after acquiring an additional 18,781 shares in the last quarter. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.